Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Numinus Wellness Inc

Healthcare CA NUMI

0.05CAD
0.00(0%)

Last update at 2026-04-22T13:30:00Z

Day Range

0.050.05
LowHigh

52 Week Range

0.050.05
LowHigh

Fundamentals

  • Previous Close 0.05
  • Market Cap16.03M
  • Volume0
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-4.61819M
  • Revenue TTM6.49M
  • Revenue Per Share TTM0.02
  • Gross Profit TTM 2.69M
  • Diluted EPS TTM-0.08

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-08-31 2023-08-31 2022-08-31 2021-08-31 2020-08-31
Type yearly yearly yearly yearly yearly
Date 2024-08-31 2023-08-31 2022-08-31 2021-08-31 2020-08-31
Income before tax -14.59971M -30.25638M -44.91589M -18.77395M -9.60056M
Minority interest - - - - -
Net income -19.64284M -30.25638M -44.88189M -21.55808M -11.85711M
Selling general administrative 11.57M 32.52M 25.17M 11.69M 6.01M
Selling and marketing expenses 0.77M - 2.19M 2.22M 0.91M
Gross profit 1.17M 8.37M 1.78M -0.08154M 0.09M
Reconciled depreciation 0.56M 2.83M 1.51M 0.72M 0.61M
Ebit -14.50094M - -28.00381M -15.87564M -7.26933M
Ebitda -13.93998M - -26.49813M -15.15864M -6.58707M
Depreciation and amortization 0.56M - 1.51M 0.72M 0.68M
Non operating income net other - - - - -
Operating income -11.70779M -26.95913M -28.00381M -15.87564M -7.26933M
Other operating expenses 15.88M - 34.94M 17.35M 8.15M
Interest expense 0.10M 0.76M 0.56M 0.11M 0.14M
Tax provision - 0.00000M -0.03400M 0.00000M -0.00788M
Interest income 0.00771M 0.00933M 0.35M 0.11M 0.13M
Net interest income -0.09107M -0.75034M -0.55766M -0.11417M -0.13480M
Extraordinary items -5.04313M - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense - - -0.03400M 2.78M 2.26M
Total revenue 4.17M 23.18M 6.49M 1.51M 0.88M
Total operating expenses 12.87M 50.14M 30.23M 15.76M 7.36M
Cost of revenue 3.00M 14.81M 4.72M 1.60M 0.79M
Total other income expense net -2.89193M -2.54691M -16.91207M -2.89831M -2.33124M
Discontinued operations - - - - -
Net income from continuing ops -14.59971M -30.25638M -44.88189M -18.77395M -9.60056M
Net income applicable to common shares -19.64284M - -44.88189M -18.77395M -9.60056M
Preferred stock and other adjustments - - - - -
Breakdown 2024-08-31 2023-08-31 2022-08-31 2021-08-31 2020-08-31
Type yearly yearly yearly yearly yearly
Date 2024-08-31 2023-08-31 2022-08-31 2021-08-31 2020-08-31
Total assets 10.77M 24.33M 52.63M 64.14M 5.12M
Intangible assets - - 0.34M - -
Earning assets - - - - -
Other current assets - - - 0.00000M 0.09M
Total liab 10.05M 10.28M 11.42M 3.31M 2.32M
Total stockholder equity 0.73M 14.05M 41.21M 60.83M 2.80M
Deferred long term liab - - - - -
Other current liab 5.79M - 0.20M 0.15M 0.17M
Common stock - - 109.20M 88.87M 18.94M
Capital stock 117.42M 112.27M 109.20M 88.87M 18.94M
Retained earnings -136.50928M -116.86644M -86.61007M -41.72818M -22.95424M
Other liab - - 0.43M 0.20M -
Good will - 0.00000M 2.17M - -
Other assets - - 0.24M 0.02M 0.01M
Cash 1.96M 8.58M 33.04M 59.29M 1.63M
Cash and equivalents - - - - -
Total current liabilities 8.61M 4.64M 4.58M 1.91M 2.01M
Current deferred revenue - - 0.24M 0.05M -
Net debt - - -25.19354M -57.68824M -1.20570M
Short term debt - - 1.44M 0.40M 0.11M
Short long term debt 0.05M 0.07M 0.06M - -
Short long term debt total - - 7.85M 1.60M 0.42M
Other stockholder equity - - 1.09M 0.50M 6.82M
Property plant equipment - - 11.38M 3.15M 2.44M
Total current assets 9.80M 12.05M 36.12M 60.97M 2.67M
Long term investments 0.00000M 2.08M 2.37M - -
Net tangible assets - - 38.70M 60.83M 2.80M
Short term investments - - - 0.00000M 0.00750M
Net receivables 0.76M 1.77M 1.60M 0.52M 0.54M
Long term debt 0.15M 0.16M 0.21M 0.00000M 0.04M
Inventory - - 0.00000M 0.00323M 0.00000M
Accounts payable 1.29M 2.89M 2.71M 1.30M 1.73M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income - - 17.54M 13.19M 6.82M
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - - 0.24M 0.02M 0.01M
Deferred long term asset charges - - - - -
Non current assets total 0.97M 12.28M 16.51M 3.17M 2.45M
Capital lease obligations 1.83M 6.96M 7.57M 1.60M 0.38M
Long term debt total - - 6.41M 1.20M 0.32M
Breakdown 2024-08-31 2023-08-31 2022-08-31 2021-08-31 2020-08-31
Type yearly yearly yearly yearly yearly
Date 2024-08-31 2023-08-31 2022-08-31 2021-08-31 2020-08-31
Investments 0.86M -0.36957M 0.12M 0.00590M 0.00590M
Change to liabilities - - -0.00337M -0.61129M 0.20M
Total cashflows from investing activities 0.86M - 0.12M -0.73925M -0.12870M
Net borrowings -0.56122M - -0.68448M -0.33431M 0.16M
Total cash from financing activities 4.54M -1.45831M 0.00734M 73.98M 7.02M
Change to operating activities - - -0.35963M -1.22759M -0.53936M
Net income -19.64284M -30.25638M -44.88189M -18.77395M -9.60056M
Change in cash -6.62034M -24.46451M -26.24892M 57.67M 1.54M
Begin period cash flow 8.58M 33.04M 59.29M 1.63M 0.09M
End period cash flow 1.96M 8.58M 33.04M 59.29M 1.63M
Total cash from operating activities -12.43427M -22.76007M -26.22965M -15.57841M -5.35546M
Issuance of capital stock 5.31M - 0.00000M 57.15M 6.13M
Depreciation 0.56M 2.83M 1.51M 0.72M 0.61M
Other cashflows from investing activities 0.03M - 1.37M -0.09729M -0.16419M
Dividends paid - - - - -
Change to inventory - - 0.00000M -0.00323M 0.00140M
Change to account receivables 0.30M -1.32493M 0.10M -0.12783M -0.17253M
Sale purchase of stock 5.31M - 0.69M 74.32M 6.75M
Other cashflows from financing activities -0.20437M - 0.69M 17.17M 1.29M
Change to netincome - - 17.41M 4.45M 4.14M
Capital expenditures 0.03M 0.38M 1.25M 0.64M 0.04M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.89M -1.06834M -0.26486M -1.96994M -0.50713M
Stock based compensation 0.56M 1.87M 3.45M 1.82M 1.88M
Other non cash items 5.19M 0.12M 13.99M 2.63M 2.26M
Free cash flow -17.50288M -23.13552M -27.47602M -16.22037M -5.39066M

Peer Comparison

Sector: Healthcare Industry: Medical Care Facilities

Company Change (CAD) Price (CAD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
NUMI
Numinus Wellness Inc		 - -% 0.05 - - 2.47 1.59 0.68 -1.3737
EXE
Extendicare Inc		 0.04 0.12% 33.84 25.21 23.92 1.59 7.26 1.62 14.43
SIA
Sienna Senior Living Inc		 0.05 0.23% 21.85 45.94 38.17 2.23 3.17 3.57 21.90
WELL
WELL Health Technologies Corp		 -0.18 4.14% 4.17 - 13.87 0.80 1.23 1.09 9.83
DR
Medical Facilities Corporation		 -0.08 0.45% 17.82 15.57 12.94 1.18 2.87 0.92 3.64

Reports Covered

Stock Research & News

View All

Profile

Numinus Wellness Inc. provides psychedelic-assisted therapy training, lab testing, and psychotherapy services in Canada and the United States. The company operates through Clinical Research Operations and Practitioner Training segments. It also provides clinical research management services to academic institutions and biotechnology companies. In addition, the company engages in the provision of education and training for research and drug development organizations to support clinical trials and commercialization efforts. Numinus Wellness Inc. is headquartered in Vancouver, Canada.

Numinus Wellness Inc

250 - 997 Seymour Street, Vancouver, BC, Canada, V6B 3M1

Key Executives

Name Title Year Born
Mr. Payton Nyquvest Co-Founder, CEO & Chairman NA
Mr. Michael Tan M.B.A. Pres, COO & Director NA
Mr. John Fong CPA, CGA CFO & Corp. Sec. NA
Dr. Evan Wood M.D., Ph.D. Chief Medical Officer NA
Dr. Paul Thielking M.D. Chief Science Officer NA
Jamie Kokoska VP of Investor Relations NA
Mr. Ian Noble Chief Communications Officer NA
Ms. Julie Saunders Chief Marketing Officer NA
Ms. Judy Varga M.Sc. Head of Laboratory Operations NA
Dr. Reid J. Robison M.D., MBA Chief Clinical Officer 1977

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.